Year-end report 2023: Scientific and regulatory progress generating international interest

•  Earnings per share, basic and diluted, were    SEK -0.09 (-0.14). •  Earnings per share, basic and diluted, were   SEK -0.09 (-0.14). •  Cash flow from operating activities totaled   SEK -2.6 (-27.7) million. •  Earnings per share, basic and diluted, were   SEK -0.30 (-0.44). •  Cash flow from operating activities for the period totaled SEK -40.3 (-65.4) million. •  Net cash totaled SEK -17.7 (28.4) million at year-end. "It is with mixed...

•  Earnings per share, basic and diluted, were
   SEK -0.09 (-0.14).

•  Cash flow from operating activities totaled
   SEK -2.6 (-27.7) million.

•  Earnings per share, basic and diluted, were
   SEK -0.30 (-0.44).

•  Cash flow from operating activities for the period totaled SEK -40.3 (-65.4) million.

•  Net cash totaled SEK -17.7 (28.4) million at year-end.

"It is with mixed feelings that we sum up 2023. Of course, we would have liked to see a better financial performance for the company, but it is gratifying that sales in Sweden were up by 31 percent. Last fall, we saw fantastic results from independent research studies that together with the coming MDR certification pave the way for a very exciting future.

Order intake from our major partners has been disappointing in recent years, but I am confident that it will pick up once MDR certification and clinical outcomes are in place. Coupled with our efforts to establish collaborations with new partners and enter new markets, this will provide Enzymatica with good growth in the coming years", said Claus Egstrand, CEO.

Significant events during the quarter

Significant events after the quarter

Other events during and after the quarter       

The full report is available on: www.enzymatica.com/investors/financial-reports 

This information is information that Enzymatica is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 08:30 a.m. CET on February 16, 2024.

For more information, please contact:

Claus Egstrand, Chief Executive Officer, Enzymatica AB
Phone: +44 7780 22 8385 | Email: claus.egstrand@enzymatica.com 

Stefan Olsson, Communication Manager, Enzymatica AB
Phone: +46 708 55 11 85 | Email: stefan.olsson@enzymatica.com

Enzymatica AB is headquartered in Lund, Sweden, and is listed on Nasdaq First North Growth Market.
For more information, please visit www.enzymatica.se. Enzymatica's Certified Adviser is Carnegie Investment Bank AB (publ).

The following files are available for download:

 

View original content:https://www.prnewswire.co.uk/news-releases/year-end-report-2023-scientific-and-regulatory-progress-generating-international-interest-302063922.html